Chromocell Therapeutics Other Current Liabilities

Chromocell Therapeutics (CHRO) currently reports a other current liabilities of $25M as of June 2026. That compares with $24K in the prior-year period — up 107265.9% year over year. Use the charts on this page to explore Chromocell Therapeutics's other current liabilities history and peer comparisons.

Chromocell Therapeutics's other current liabilities increased from $24K to $25M — a 107265.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chromocell Therapeutics reported $25M in other current liabilities as of June 2026. That compares with $24K in the prior-year period — up 107265.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chromocell Therapeutics, and consider following CHRO for alerts when major investors trade the stock.